| Tookad (padeliporfin) / ImPact Biotech |
NCT03617003: Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) |
|
|
| Active, not recruiting | 1 | 30 | US | WST11 mediated vascular targeted phototherapy (VTP), Endoscopy | Memorial Sloan Kettering Cancer Center | Upper Tract Urothelial Carcinoma | 12/24 | 12/24 | | |
NCT05919238: Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | 1 | 30 | US | Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, Padeliporfin VTP | Impact Biotech Ltd, Impact biotech Ltd. | Locally Advanced Unresectable Pancreatic Adenocarcinoma | 05/26 | 10/26 | | |
NCT03133650: A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing |
|
|
| Active, not recruiting | 1 | 12 | US, RoW | WST 11-mediated VTP therapy | Memorial Sloan Kettering Cancer Center, Weizmann Institute of Science, Steba Biotech S.A. | Esophagogastric Cancer, Moderate to Severe Dysphagia | 02/25 | 02/25 | | |
NCT05918783: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer |
|
|
| Not yet recruiting | 1 | 36 | NA | Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, Padeliporfin VTP | Impact Biotech Ltd, Impact biotech Ltd. | Peripheral Lung Tumor | 05/26 | 12/27 | | |
